BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Bryan Paul SchneiderGuanglong JiangTarah Jean BallingerFei ShenChristopher ChitambarRita NandaCarla FalksonFilipa C LynceChristopher M GallagherClaudine IsaacsMarcelo BlayaElisavet PaplomataRadhika WallingKaren DailyReshma L MahtaniMichael A ThompsonRobert GrahamMaureen E CooperDean C PavlickLee A AlbackerJeffrey GreggJeffrey P SolzakYu-Hsiang ChenCasey L BalesErica L CantorBradley A HancockNawal KassemPaul HelftBert O'NeilAnna Maria V StornioloSunil S BadveKathy D MillerMilan RadovichPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Genomically directed therapy was not superior to TPC for patients with residual TNBC after NAC. Capecitabine should remain the standard of care; however, the activity of other agents in this setting provides rationale for testing optimal combinations to improve outcomes. Circulating tumor DNA should be considered a standard covariate for trials in this setting.
Keyphrases
- circulating tumor
- cell free
- open label
- circulating tumor cells
- healthcare
- phase iii
- emergency department
- placebo controlled
- double blind
- primary care
- palliative care
- clinical trial
- transcription factor
- randomized controlled trial
- phase ii study
- adipose tissue
- metabolic syndrome
- type diabetes
- radiation therapy
- cell therapy
- glycemic control